Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1046 of 6351
-
Can a softer chemo regimen spare older breast cancer patients?
Disease control OngoingThis study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for advanced bowel cancer patients too frail for strong chemo
Disease control OngoingThe main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.
Phase 3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo therapy aims to halt prostate cancer spread
Disease control OngoingAs in other solid tumours, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis compared with patients with extensive metastatic disease. Survival of patients with three or f…
Phase 2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a cancer drug slow down these brain tumors?
Disease control CompletedRecent data demonstrate that in IDH-mutant gliomas, 2 hydroxy-glutarate production induces a homologous recombination defect that renders tumor cells exquisitely sensitive to poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors, including olaparib (Lynparza; AstraZe…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 26, 2026 16:05 UTC
-
Could a simple TB test save kids with pneumonia?
Diagnosis CompletedDespite progress in reducing tuberculosis (TB) incidence and mortality in the past 20 years, TB is a top ten cause of death in children under 5 years worldwide. However, childhood TB remains massively underreported and undiagnosed, mostly because of the challenges in confirming i…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human mo…
Phase 1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy. This means it may help the immune system fight cancer. Such therapie…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Immune cells injected directly into brain show promise for kids with tough tumors
Disease control CompletedThis is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells that are lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling cathe…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Surgical radiation zaps pancreatic tumors from inside
Disease control OngoingThis research study is studying an intervention as a possible treatment for pancreatic cancer.
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a drug slow rare brain disease? new study uses Real-World data to find out
Disease control OngoingThe purpose of this study is to leverage two sources of real-world data (RWD) to assess the effectiveness of troriluzole after three years of treatment in patients with SCA by comparison to an external control of untreated patients who were followed in a natural history cohort. …
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Heart surgery tweak could slash stroke risk in millions
Prevention OngoingAtrial fibrillation is a heart rhythm disorder that often occurs after heart surgery. During atrial fibrillation blood cloths may form, predominantly in the left atrial appendage, a small sac in the wall of the left side of the heart. Some heart surgeons close this appendage to p…
Sponsor: Helena DOMINGUEZ • Aim: Prevention
Last updated Jun 27, 2026 08:11 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Phase 1/2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in tough pancreatic cancer battle
Disease control OngoingZolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's i…
Phase 2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New combo therapy shows promise for kids with aggressive leukemia
Disease control OngoingThis study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia. The study has two parts: Part 1 to define the Recommended Phase 2 Dose, and…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New combo therapy for lung cancer shows promise in major trial
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug KPL-716 aims to stop the itch of prurigo nodularis
Symptom relief CompletedStudy of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN).
Phase 2 • Sponsor: Genentech, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Can a steroid save kids from septic shock?
Disease control Recruiting nowSHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hy…
Phase 3 • Sponsor: Jerry Zimmerman • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug could slow rare brain disease that steals balance
Disease control OngoingThe purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy duo targets rare, Mutation-Rich breast cancer
Disease control OngoingThis research study is studying a drug combination of nivolumab and ipilimumab as a possible treatment for hypermutated HER2 negative breast cancer. The drugs involved in this study are: * Nivolumab (Opdivo ®) * Ipilimumab (Yervoy ®)
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
A stumble before memory slips? study tests if falls predict Alzheimer's
Knowledge-focused CompletedThis longitudinal cohort study investigates cognitively normal participants with and without preclinical Alzheimer disease (AD) in order to examine: (1) the relationship between falls and functional mobility in preclinical stages of AD; and (2) a hypothesized model of central and…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC